A monoclonal antibody of citalopram, nucleic acid molecules, vectors, detection kits, detection reagents and application thereof
By developing a citalopram monoclonal antibody with a specific sequence, a detection kit was prepared, solving the problems of long detection time and low sensitivity of citalopram and achieving highly sensitive citalopram detection.
CN121895458BActive Publication Date: 2026-06-23THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
5 Cites 0 Cited by
Patent Information
- Application Number
- CN202610363293.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-24
- Publication Date
- 2026-06-23
- Estimated Expiration
- 2046-03-24
AI Technical Summary
Technical Problem
Existing citalopram detection methods are time-consuming, complex to operate, and have low sensitivity, making it difficult to achieve efficient and specific detection.
Method used
Develop a monoclonal antibody against citalopram containing specific heavy and light chain variable region sequences for the preparation of a citalopram detection kit for detection using immunological methods.
Benefits of technology
The detection sensitivity of citalopram was improved, with a lower limit of detection of 0.06807 ng/mL, an IC50 of 0.888 ng/mL, and a quantitative detection range of 0.17567~4.49194 ng/mL. It also showed no significant cross-reactivity with other similar drugs.
✦ Generated by Eureka AI based on patent content.
Abstract
The application belongs to the field of rapid detection of SSRIs drugs, and particularly relates to a monoclonal antibody of citalopram, a nucleic acid molecule, a carrier, a detection kit, a detection reagent and application thereof. The monoclonal antibody of citalopram comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, the light chain variable region comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, the sequence of the heavy chain CDR1 is shown as SEQ ID NO. 1, the sequence of the heavy chain CDR2 is shown as SEQ ID NO. 2, and the sequence of the heavy chain CDR3 is shown as SEQ ID NO. 3. The monoclonal antibody of the application has high sensitivity for citalopram detection, the minimum detection limit is 0.06807 ng / mL, the quantitative detection range is 0.17567-4.49194 ng / mL, and the specificity is strong.
Need to check novelty before this filing date? Find Prior Art